Search research articles
Contact Us
Filters
Showing results (1-10 of 23) with videos related to
Page
of 3
Sort By:
Annals of Internal Medicine
|
March 5, 2004
Management of the clinically inapparent adrenal mass
Paul M Copeland
Nature Clinical Practice. Endocrinology & Metabolism
|
December 5, 2006
How successful are commercial weight-loss programs?
Paul M Copeland
The Lancet. Psychiatry
|
September 12, 2015
Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses
David C Henderson, Brenda Vincenzi, Nicolas V Andrea, et al.
Journal of Clinical Psychopharmacology
|
August 27, 2011
Placebo-controlled pilot study of ramelteon for adiposity and lipids in patients with schizophrenia
Christina P C Borba, Xiaoduo Fan, Paul M Copeland, et al.
Journal of Clinical Psychopharmacology
|
February 25, 2011
No effect of single-dose intranasal insulin treatment on verbal memory and sustained attention in patients with schizophrenia
Xiaoduo Fan, Paul M Copeland, Emily Y Liu, et al.
Journal of the American College of Radiology : JACR
|
March 3, 2009
Adrenal masses
Janet C Miller, Michael A Blake, Giles W Boland, et al.
Clinical Schizophrenia & Related Psychoses
|
November 23, 2017
Clozapine, Diabetes Mellitus, Cardiovascular Risk and Mortality: Results of a 21-Year Naturalistic Study in Patients with Schizophrenia and Schizoaffective Disorder
Katlyn L Nemani, M Claire Greene, Melissa Ulloa, et al.
Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists
|
May 3, 2013
An exploratory study examining lipid-lowering medications in reducing fasting serum lipids in schizophrenia patients treated with atypical antipsychotics
Brenda Vincenzi, Christina Pc Borba, Deborah A Gray, et al.
The Journal of Clinical Psychiatry
|
May 4, 2007
Elevated hemoglobin A1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychotics
David C Henderson, Enrico Cagliero, Paul M Copeland, et al.
Biological Psychiatry
|
August 22, 2006
Higher fasting serum insulin is associated with increased resting energy expenditure in nondiabetic schizophrenia patients
Xiaoduo Fan, Ellen J Anderson, Paul M Copeland, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 23) with videos related to
Sort By:
Page
of 3
Annals of Internal Medicine
|
March 5, 2004
Management of the clinically inapparent adrenal mass
Paul M Copeland
Nature Clinical Practice. Endocrinology & Metabolism
|
December 5, 2006
How successful are commercial weight-loss programs?
Paul M Copeland
The Lancet. Psychiatry
|
September 12, 2015
Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses
David C Henderson, Brenda Vincenzi, Nicolas V Andrea, et al.
Journal of Clinical Psychopharmacology
|
August 27, 2011
Placebo-controlled pilot study of ramelteon for adiposity and lipids in patients with schizophrenia
Christina P C Borba, Xiaoduo Fan, Paul M Copeland, et al.
Journal of Clinical Psychopharmacology
|
February 25, 2011
No effect of single-dose intranasal insulin treatment on verbal memory and sustained attention in patients with schizophrenia
Xiaoduo Fan, Paul M Copeland, Emily Y Liu, et al.
Journal of the American College of Radiology : JACR
|
March 3, 2009
Adrenal masses
Janet C Miller, Michael A Blake, Giles W Boland, et al.
Clinical Schizophrenia & Related Psychoses
|
November 23, 2017
Clozapine, Diabetes Mellitus, Cardiovascular Risk and Mortality: Results of a 21-Year Naturalistic Study in Patients with Schizophrenia and Schizoaffective Disorder
Katlyn L Nemani, M Claire Greene, Melissa Ulloa, et al.
Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists
|
May 3, 2013
An exploratory study examining lipid-lowering medications in reducing fasting serum lipids in schizophrenia patients treated with atypical antipsychotics
Brenda Vincenzi, Christina Pc Borba, Deborah A Gray, et al.
The Journal of Clinical Psychiatry
|
May 4, 2007
Elevated hemoglobin A1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychotics
David C Henderson, Enrico Cagliero, Paul M Copeland, et al.
Biological Psychiatry
|
August 22, 2006
Higher fasting serum insulin is associated with increased resting energy expenditure in nondiabetic schizophrenia patients
Xiaoduo Fan, Ellen J Anderson, Paul M Copeland, et al.
Page
of 3